Regeneron Pharmaceuticals, Inc.

NasdaqGS:REGN Stock Report

Market Cap: US$76.7b

Regeneron Pharmaceuticals Past Earnings Performance

Past criteria checks 4/6

Regeneron Pharmaceuticals has been growing earnings at an average annual rate of 4.1%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 11.2% per year. Regeneron Pharmaceuticals's return on equity is 15%, and it has net margins of 31.1%.

Key information

4.1%

Earnings growth rate

4.1%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate11.2%
Return on equity15.0%
Net Margin31.1%
Last Earnings Update31 Dec 2024

Recent past performance updates

Recent updates

Regeneron Q4 Earnings: Dividend And Dupixent Drive Solid Quarter - Eylea To Strike Back In 2025

Feb 04

Regeneron: Phase III Success In Skin Cancer For Libtayo

Jan 15

Regeneron's Diversified Growth Makes It My Top Biopharma Pick For 2025

Jan 05

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Dec 13
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron: Recent Bear Run May Be Justified -- Pharma Faces A Testing 2025

Dec 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings

Nov 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Price Is Out Of Tune With Earnings

Regeneron: The Biotech Stock To Buy Now

Nov 19

Regeneron: Buying A Promising Pipeline At A Fair Price (Rating Upgrade)

Nov 04

Amgen Biosimilar And EYLEA Patent Dispute: What It Means For Regeneron Investors

Sep 25

Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Sep 09
Is Regeneron Pharmaceuticals (NASDAQ:REGN) Using Too Much Debt?

Regeneron Stock: Valuation Now Demands More Growth

Aug 26

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Aug 22
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 81% Above Its Share Price

Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Aug 04
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron's Robust Pipeline And Financial Health Signal Continued Growth

Aug 02

Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings

Jul 11

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

Jun 08
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why

These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

May 21
These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well

Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks

May 06

Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Apr 30
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing

Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Apr 10
Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?

Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate

Mar 26

Revenue & Expenses Breakdown

How Regeneron Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqGS:REGN Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2414,2024,4132,9540
30 Sep 2413,8474,6552,9000
30 Jun 2413,4894,3222,826265
31 Mar 2413,1003,8582,7190
31 Dec 2313,1173,9542,6310
30 Sep 2313,0973,9912,5540
30 Jun 2312,6714,2992,4431,938
31 Mar 2312,3704,1832,2670
31 Dec 2212,1734,3382,1160
30 Sep 2213,7105,3702,0150
30 Jun 2214,2275,6871,9310
31 Mar 2216,5087,9341,8690
31 Dec 2116,0728,0751,8250
30 Sep 2113,5436,9961,5690
30 Jun 2112,3846,2051,4510
31 Mar 219,1984,0041,3840
31 Dec 208,4973,5131,3460
30 Sep 207,9383,1561,4590
30 Jun 207,3872,9841,4370
31 Mar 207,0132,2791,3830
31 Dec 196,5582,1161,3420
30 Sep 196,6222,1441,3810
30 Jun 196,5422,0691,4460
31 Mar 196,5722,4281,5170
31 Dec 185,1462,4441,1270
30 Sep 186,3651,7981,4750
30 Jun 186,2031,5911,4120
31 Mar 186,0651,4281,3540
31 Dec 175,8721,1991,3200
30 Sep 175,5171,2781,2360
30 Jun 175,2361,1551,2000
31 Mar 174,9799631,1850
31 Dec 164,8608961,1780
30 Sep 164,7327971,1470
30 Jun 164,6497431,0870
31 Mar 164,4357419690
31 Dec 154,1046368390
30 Sep 153,8085717190
30 Jun 153,3964446530
31 Mar 153,0633465750
31 Dec 142,8203385190
30 Sep 142,6283454260
30 Jun 142,4994033800
31 Mar 142,2913943550

Quality Earnings: REGN has high quality earnings.

Growing Profit Margin: REGN's current net profit margins (31.1%) are higher than last year (30.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: REGN's earnings have grown by 4.1% per year over the past 5 years.

Accelerating Growth: REGN's earnings growth over the past year (11.6%) exceeds its 5-year average (4.1% per year).

Earnings vs Industry: REGN earnings growth over the past year (11.6%) did not outperform the Biotechs industry 23.5%.

Return on Equity

High ROE: REGN's Return on Equity (15%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/06 23:10
End of Day Share Price 2025/02/06 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Regeneron Pharmaceuticals, Inc. is covered by 60 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research